Literature DB >> 12958359

Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1.

Yili Yin1, Bénédicte Manoury, Robin Fåhraeus.   

Abstract

The glycine-alanine repeat domain (GAr) of Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1) prevents major histocompatibility complex (MHC) class I-restricted presentation of EBNA1 epitopes to cytotoxic T cells. This effect has previously been attributed to the ability of GAr to inhibit its own proteasomal degradation. Here we show, both in vitro and in vivo, that GAr also inhibits messenger RNA translation of EBNA1 in cis and that this effect can be distinguished from its effect on proteasomal degradation. Hence, inhibition of messenger RNA translation, but not protein degradation, is essential to prevent antigen presentation on MHC class I molecules. Thus, by minimizing translation of the EBNA1 transcript, cells expressing EBNA1 avoid cytotoxic T cell recognition. At the same time, blocking degradation maintains the EBNA1 expression level.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12958359     DOI: 10.1126/science.1088902

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  113 in total

Review 1.  Virus subversion of protective immunity.

Authors:  Eric W Hewitt; Gillian E Dugan
Journal:  Curr Allergy Asthma Rep       Date:  2004-09       Impact factor: 4.806

Review 2.  DRiPs solidify: progress in understanding endogenous MHC class I antigen processing.

Authors:  Jonathan W Yewdell
Journal:  Trends Immunol       Date:  2011-09-29       Impact factor: 16.687

Review 3.  Adoptive T-Cell Immunotherapy.

Authors:  Stephen Gottschalk; Cliona M Rooney
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

Review 4.  Viral evasion of the MHC class I antigen-processing machinery.

Authors:  Sandra Loch; Robert Tampé
Journal:  Pflugers Arch       Date:  2005-08-06       Impact factor: 3.657

5.  Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion.

Authors:  Maaike E Ressing; Daphne van Leeuwen; Frank A W Verreck; Sinéad Keating; Raquel Gomez; Kees L M C Franken; Tom H M Ottenhoff; Melanie Spriggs; Ton N Schumacher; Lindsey M Hutt-Fletcher; Martin Rowe; Emmanuel J H J Wiertz
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Autorepression of Epstein-Barr virus nuclear antigen 1 expression by inhibition of pre-mRNA processing.

Authors:  Mikio Yoshioka; Michelle M Crum; Jeffery T Sample
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

7.  mRNA translation regulation by the Gly-Ala repeat of Epstein-Barr virus nuclear antigen 1.

Authors:  Sebastien Apcher; Anastassia Komarova; Chrysoula Daskalogianni; Yili Yin; Laurence Malbert-Colas; Robin Fåhraeus
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

8.  Kaposi's sarcoma-associated herpesvirus K7 protein targets a ubiquitin-like/ubiquitin-associated domain-containing protein to promote protein degradation.

Authors:  Pinghui Feng; Christopher W Scott; Nam-Hyuk Cho; Hiroyuki Nakamura; Young-Hwa Chung; Mervyn J Monteiro; Jae U Jung
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

Review 9.  Immune escape by Epstein-Barr virus associated malignancies.

Authors:  Christian Münz; Ann Moormann
Journal:  Semin Cancer Biol       Date:  2008-10-19       Impact factor: 15.707

10.  Slippery substrates impair function of a bacterial protease ATPase by unbalancing translocation versus exit.

Authors:  Priscilla Hiu-Mei Too; Jenny Erales; Joana Danica Simen; Antonija Marjanovic; Philip Coffino
Journal:  J Biol Chem       Date:  2013-03-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.